2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Irinotecan
31
Paclitaxel
27
Gemcitabine
27
Cisplatin
25
Docetaxel
20
Oxaliplatin
16
Fluorouracil
15
alvocidib
13
Leucovorin
13
Carboplatin
13
Capecitabine
12
Bortezomib
10
Early Intervention, Educational
9
Topotecan
8
Taxes
8
Bevacizumab
7
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
7
ixabepilone
6
Vorinostat
6
Temozolomide
6
Sorafenib
6
Immunohistochemistry
6
Immunoenzyme Techniques
6
7-hydroxystaurosporine
6
tanespimycin
5
Pharmacogenomic Testing
5
Pemetrexed
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Etoposide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unspecified Adult Solid Tumor, Protocol Specific
×
bempegaldesleukin
×
Clear all
NCT02869295
2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2
Completed
28 enrolled
16 charts